#USA #New York #GeneDx Holdings #Sarbanes-Oxley #Joe Levi

Upcoming Deadlines for GeneDx Holdings Corp Investors

In a recent alert from SueWallSt, investors in GeneDx Holdings Corp (NASDAQ: WGS) are reminded of the looming deadline regarding a significant securities class action lawsuit. This lawsuit emerges amidst serious allegations against GeneDx’s top executives, who are now named as individual defendants in the suit.

Background of the Case

The securities class action targets key corporate players, specifically CEO Katherine Stueland and CFO Kevin Feeley. This legal action arises from the company’s substantial loss of investor value, with WGS shares plummeting by 49.20%—a loss equating to $33.42 per share. These shocking numbers followed the company’s recent disclosure of a $31.2 million impairment charge along with drastic cuts to their revenue guidance, slashing expectations by around $65 million.

The court has set August 3, 2026, as the deadline for investors to apply for the lead plaintiff appointment. This upcoming date is crucial for any shareholder wishing to take a more active role in the lawsuit

Who Are the Defendants?

The lawsuit names both Katherine Stueland and Kevin Feeley as individual defendants. Both executives are under scrutiny for their alleged control over the company's communications with investors, including SEC filings, press announcements, and presentations. Reports suggest that they had prior access to the misleading public statements and could have corrected inaccuracies regarding the company’s financial health and operational outcomes.

The crux of the complaint rests on the claims that these executives not only failed to uphold their responsibilities regarding corporate communications but also knowingly misled shareholders about significant issues pertaining to the viability of the Fabric Genomics division.

Legal Claims Under Section 20(a)

The claims detailed in the lawsuit utilize Section 20(a) of the Securities Exchange Act of 1934, which holds controlling individuals accountable for violations of securities laws. The lawsuit posits that the CEO and CFO fit this designation, following their high-level positions within the company. Their involvement in the daily operations and personal awareness of the discrepancies between reported and actual performance further bolsters these claims.

Allegedly, during earnings calls, misleading guidance about the Fabric Genomics acquisition was communicated to shareholders, creating misunderstandings about the company's financial trajectory.

Sarbanes-Oxley Act Compliance

Adding another layer to the case, both Stueland and Feeley signed certifications under the Sarbanes-Oxley Act, asserting the completeness and truthfulness of the company's financial filings. However, the allegations indicate that they might have certified this information despite being aware of significant operational failures within GeneDx. This aspect of potential recklessness or negligence is critical, as it directly implicates them in the misinformation spread to shareholders.

How Should Investors Proceed?

For investors who purchased shares of GeneDx during the specified class period between April 16, 2025, and May 4, 2026, there are steps you should consider taking to ensure eligibility for any potential recovery. Investors are encouraged to gather brokerage records detailing purchase dates, share quantities, and prices paid. Contacting SueWallSt offers a pathway for those wishing to evaluate their options further.

Additionally, many investors might be worried about needing to appear in court or give testimonies. Fortunately, this is unlikely, as most class members simply need to submit a claim form to claim their share of any awarded recovery.

FAQs About the WGS Lawsuit

• - Who is being sued in this class action? The lawsuit names GeneDx Holdings Corp. along with its CEO and CFO, both of whom have been implicated in the misleading communication of financial data.
• - What is the lead plaintiff application deadline? Investors have until August 3, 2026, to apply for this pivotal role.
• - What should WGS investors do now? Investors should compile evidence of their share purchases and reach out for a case evaluation to understand their chances for recovery.

Conclusion

The unraveling situation surrounding GeneDx Holdings Corp serves as a warning to investors regarding corporate disclosures and the importance of accurate financial reporting. With the deadline closing in, taking prompt action is advised for those who wish to pursue justice through this class action. For further information or to get help with this process, reach out to Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.